KR101834550B1 - Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component - Google Patents
Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component Download PDFInfo
- Publication number
- KR101834550B1 KR101834550B1 KR1020150171156A KR20150171156A KR101834550B1 KR 101834550 B1 KR101834550 B1 KR 101834550B1 KR 1020150171156 A KR1020150171156 A KR 1020150171156A KR 20150171156 A KR20150171156 A KR 20150171156A KR 101834550 B1 KR101834550 B1 KR 101834550B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- caffeoyl
- composition
- disease
- nitric oxide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- OEQLAEKPFUKPTL-DNLSIVOMSA-N C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(CCC1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O Chemical compound C(\C=C\C1=CC(O)=C(O)C=C1)(=O)[C@]1(CC(C[C@H](C1(O)C(CCC1=CC(O)=C(O)C=C1)=O)O)(C(=O)O)O)O OEQLAEKPFUKPTL-DNLSIVOMSA-N 0.000 title claims abstract description 24
- 208000019553 vascular disease Diseases 0.000 title abstract description 16
- 210000003556 vascular endothelial cell Anatomy 0.000 claims abstract description 24
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 206010020772 Hypertension Diseases 0.000 claims abstract description 9
- 241000047339 Salicornia brachystachya Species 0.000 claims abstract description 6
- 208000025494 Aortic disease Diseases 0.000 claims abstract description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 4
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 claims abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 58
- 235000013376 functional food Nutrition 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- -1 phospho Chemical class 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 abstract description 5
- 229910017604 nitric acid Inorganic materials 0.000 abstract description 5
- 241000201895 Salicornia Species 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 abstract description 2
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 10
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 210000003979 eosinophil Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- BEVHTVRRVVEMEF-UHFFFAOYSA-N [6'-acetyloxy-4-amino-2',7'-difluoro-5-(methylamino)-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate Chemical compound C12=CC(F)=C(OC(C)=O)C=C2OC2=CC(OC(C)=O)=C(F)C=C2C21OC(=O)C1=C(N)C(NC)=CC=C21 BEVHTVRRVVEMEF-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108030005456 Calcium/calmodulin-dependent protein kinases Proteins 0.000 description 2
- 244000132059 Carica parviflora Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BJTLSPOVXMBXRZ-UHFFFAOYSA-N DAF-FM dye Chemical compound OC(=O)C1=C(N)C(NC)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BJTLSPOVXMBXRZ-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZMZINYUKVRMNTG-UHFFFAOYSA-N acetic acid;formic acid Chemical compound OC=O.CC(O)=O ZMZINYUKVRMNTG-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to 3-dihydro-4-five days cafe cafe five days quinolyl prevention, a composition for improving or treating vascular disease comprising the acid as an active ingredient, 3-isolated from Salicornia (Salicornia herbacea) according to the invention When 3-caffeoyl-4-dihydrocaffeoylquinic acid was administered to vascular endothelial cells, the expression of phospho-eNOS (endothelial nitric oxide synthase) was increased and NO (nitric acid) And the generated NO is liberated into blood vessels and induces relaxation of smooth muscle to relax the blood vessels. Therefore, blood vessels such as hypertension, arteriosclerosis, coronary artery disease, cerebrovascular disease, peripheral vascular disease, or aortic disease Can be usefully used as a composition for preventing, ameliorating or treating diseases.
Description
The present invention relates to a composition for preventing, improving or treating vascular diseases containing 3-caffeoyl-4-dihydrocafeoyl-quinic acid as an active ingredient, and more particularly, to a composition for preventing, Which comprises 3-caffeoyl-4-dihydrocaffeoyl-quinic acid as an active ingredient, to a composition for preventing, improving or treating vascular diseases.
The endothelium of blood vessels plays an important role in maintaining vascular homeostasis in vasoreactivity, platelet activation, leukocyte adhesion, proliferation and migration of smooth muscle cells. The nitric oxide (NO) produced in the vascular endothelium is the most potent substance to protect the blood vessels. It relaxes the vascular smooth muscle cells and expands blood vessels. The damaged NO signaling system is atherosclerosis and hypertension, And the like. Nitric oxide synthase (NOS) is an enzyme that catalyzes the conversion of O 2 and the cofactor nicotinamide adenine dinucleotide phospate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) Arginine is a group of enzymes that synthesize NO from the terminal nitrogen atom of L-arginine in the presence of heme, tetrahydrobiopterin (BH4). Of the known NOSs, n-NOS (neuronal nitric oxide (eosinophils), eosinophils (eosinophils), eosinophils (eosinophils), eosinophils (eosinophils), and eosinophils.
On the other hand, Salicornia herbacea ( Salicornia herbacea ) is an annual plant that grows in the coastal waters of Korea. It is also known as a mildew or mullet. It is also called a coral reef because its whole shape resembles a coral. It is recorded as "green tea" in the Chinese medicine medical book "Chinese medicine" which is the best medicine book in China, and "Shincho", "Chinese medicine" or " Has been used. It removes toxins and succulents accumulated in the body and has excellent therapeutic effect on cancer, myoma, sinusitis, hypertension, hypotension, back pain, diabetes, bronchial asthma, hypothyroidism, hyperthyroidism, skin disease, arthritis, nephritis or various incurable diseases It is known as the amazing herb that it has.
Korean Patent Publication No. 2011-0081007 discloses a composition for prevention or improvement of hypertension including a fermented product of green tea, Korean Patent No. 1323157 discloses a composition for preventing or improving hypertension comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid As an active ingredient, a pharmaceutical composition for inhibiting cancer metastasis. However, a composition for preventing, improving or treating vascular diseases containing 3-caffeoyl-4-dihydrocafeoylquinic acid as an active ingredient of the present invention has not yet been disclosed.
The present invention has been made in view of the above-mentioned needs, and the present inventors have found that Salicornia 3-caffeoyl-4-dihydrocaffeoylquinic acid was isolated from herbacea and the 3-caffeoyl-4-dihydrocaffeoylquinic acid was treated with vascular endothelial cells (Endothelial nitric oxide synthase), thereby increasing the amount of NO (nitric acid) produced. The present invention has been completed based on this finding.
In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for preventing or ameliorating vascular diseases containing 3-caffeoyl-4-dihydrocaffeoylquinic acid or a salt thereof as an active ingredient Functional food composition.
The present invention also relates to a pharmaceutical composition for preventing or treating vascular diseases containing 3-caffeoyl-4-dihydrocaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient Lt; / RTI >
When 3-caffeoyl-4-dihydrocaffeoylquinic acid isolated from Salicornia herbacea according to the present invention was treated with vascular endothelial cells, phospho-eNOS (endothelial nitric acid (nitric acid) production is increased by increasing the expression level of nitric oxide synthase (NO synthase), and the generated NO is liberated into blood vessels to induce relaxation of smooth muscle to relax blood vessels. Thus, hypertension, arteriosclerosis, coronary artery disease , Vascular diseases such as cerebrovascular disease, peripheral vascular disease, or aortic disease, and the like.
FIG. 1 is a graph showing the effect of 3-caffeoyl-4-dihydrocaffeoylquinic acid on the vascular endothelial cells at various concentrations according to an embodiment of the present invention. ). CDCQ is 3-caffeoyl-4-dihydrocaffeoylquinic acid.
FIG. 2 is a graph showing the results of treatment of 3-caffeoyl-4-dihydrocaffeoylquinic acid according to an embodiment of the present invention on endothelial cells at various concentrations, phospho-eNOS (endothelial nitric oxide synthase). β-actin is a loading control.
FIG. 3 is a graph illustrating the effect of 3-caffeoyl-4-dihydrocaffeoylquinic acid (NO) on nitric oxide (NO) when treated with various concentrations of vascular endothelial cells according to an embodiment of the present invention. (A) and fluorescence intensity graph (B), respectively.
FIG. 4 is a graph showing that when 3-caffeoyl-4-dihydrocaffeoylquinic acid is treated with vascular endothelial cells over time, phospho-eNOS and NO (A) and CaMKIIa (calcium / calmodulin-dependent protein kinase) (B), which are related to the signal transduction pathway. β-actin is a loading control.
FIG. 5 is a graph showing the results of pretreatment of H-89 and KN-93 which are inhibitors of PKA and CaMKIIa according to an embodiment of the present invention, respectively, on vascular endothelial cells, and then 3-caffeoyl -4-dihydrocaffeoylquinic acid), the expression level of phospho-eNOS is shown. β-actin is a loading control.
FIG. 6 is a graph showing the results of pretreatment of vascular endothelial cells with H-89 and KN-93, inhibitors of PKA and CaMKIIa, respectively, according to an embodiment of the present invention, and then 3-caffeoyl-4-dihydro caffeoylquinic acid (3- caffeoyl-4-dihydrocaffeoylquinic acid), the degree of formation of NO (nitric oxide) is represented by a total fluorescence microscope photograph (A) and a fluorescence intensity graph (B).
In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or ameliorating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid or a salt thereof as an active ingredient Functional food composition.
The 3-caffeoyl-4-dihydrocaffeoic acid may be isolated from Salicornia herbacea , but is not limited thereto.
The vascular disease may be, but is not limited to, atherosclerosis, hypertension, cerebrovascular disease, peripheral vascular disease, or aortic disease.
The health functional food composition for preventing or ameliorating the vascular disease may increase the expression amount of phospho-eNOS (endothelial nitric oxide synthase) in vascular endothelial cells to increase the production amount of nitric acid (NO), but the present invention is not limited thereto.
When the health functional food composition for preventing or ameliorating vascular diseases according to the present invention is used as a food additive, the health functional food composition may be added as it is or may be used together with other food or food ingredients, . Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term intake for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, , A drink, an alcoholic beverage, and a vitamin complex, all of which include health foods in a conventional sense.
In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, For example, xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
In addition to the above health functional food composition, it is also possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.
The present invention also relates to a pharmaceutical composition for preventing or treating vascular diseases containing 3-caffeoyl-4-dihydrocaffeoylquinic acid or a pharmaceutically acceptable salt thereof as an active ingredient Lt; / RTI >
The salt is not particularly limited as long as it is pharmaceutically acceptable so long as it is pharmaceutically acceptable and includes, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, , Benzenesulfonic acid, toluenesulfonic acid, and naphthalenesulfonic acid. In addition to acid addition salts, additional base salts such as sodium hydroxide, potassium hydroxide, triethylamine, tertiary-butylamine may also be used.
The pharmaceutical composition for the prevention or treatment of vascular diseases of the present invention may further comprise an appropriate carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition.
The pharmaceutical composition for the prevention or treatment of vascular diseases according to the present invention can be administered orally or parenterally in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories, And the like. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Various compounds or mixtures including cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
A suitable dose of the pharmaceutical composition of the present invention may be variously prescribed by factors such as the formulation method, the administration method, the age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient .
The pharmaceutical composition of the present invention may be administered orally or parenterally. In the case of parenteral administration, the composition may be administered topically to the skin, intravenously, subcutaneously, intramuscularly, intraperitoneally, or transdermally.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
Example One. From Hamcho 3-caffeoyl-4-dihydro Cafe oil Quinic detach
1.5 kg of the dried plant extracts collected from the tidal flats of the west coast were cut off and extracted with 100% (v / v) methanol for 3 days. After filtration under reduced pressure, the methanol concentrate was concentrated under reduced pressure in a water bath at 60 ° C., Lt; / RTI > The methanol extract suspended in distilled water was extracted with shaking with 2 l of ethyl acetate to obtain a water layer. The water layer was concentrated under reduced pressure in a water bath at 60 캜 to remove ethyl acetate present in the water layer. The water layer with ethyl acetate removed was adsorbed on Diaion HP-20 column chromatography equilibrated with distilled water, washed with water, and then extracted with 30% (v / v) methanol solution to obtain an active substance To obtain an active fraction. Thereafter, the active fractions were concentrated under reduced pressure, dissolved in a small amount of methanol, and developed on a Sephadex LH-20 gel column chromatography equilibrated with methanol to obtain active fractions. The fractions were separated by a YMC gel ODS column chromatography (V / v) acetonitrile aqueous solution at acidic conditions using YMC gel ODS column chromatography using high performance liquid chromatography. As a result of instrumental analysis, the compound 3-caffeoyl-4-dihydrocaffeoylquinic acid (CDCQ, molecular formula: C 25 H 26 O 12 ) was obtained.
Example 2. In vascular endothelial cells, 3-caffeoyl-4-dihydro Cafe oil Quinic Cytotoxicity check
In order to confirm that 3-caffeoyl-4-dihydrocaffeoylquinic acid (CDCQ) of the present invention is a compound without cytotoxicity, 1, 5, 10, 20 And 50 μM of CDCQ were cultured for 24 hours and cultured for 24 hours using MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) assay kit (USB corporation, Cleveland, OH USA) Cell viability was measured. For this, EA.hy926 cells were divided into 48-well plates at a density of 1 × 10 4 cells / well and cultured for 24 hours. Then, the CDCQ was diluted to different concentrations while replacing 500 μl of the cell culture medium, Lt; / RTI > Thereafter, the treated medium for each sample was collected, treated with 0.2 mg / ml of MTT solution in a 96-well plate, and reacted for 30 minutes. After the completion of the reaction, the supernatant was removed, and 100 mu l of DMSO (dimethyl sulfoxide) was added to dissolve the generated formazan crystals, and the absorbance at 550 nm was measured with a microplate analyzer. As a result, when the CDCQ of the present invention was treated with the endothelial cells of the present invention as shown in FIG. 1, no cytotoxicity was observed at a concentration of 50 μM or less (Fig. 1).
Example 3. In vascular endothelial cells, 3-caffeoyl-4-dihydro Cafe oil Quinic acid Depending on the treatment phospho - eNOS ( endothelial nitric oxide synthase ),
EA.hy926 cells were treated with 3-caffeoyl-4-dihydrocaffeoylquinic acid (CDCQ) of the present invention for 1 hour to obtain total cell lysates And the expression of phospho - eNOS (endothelial nitric oxide synthase) in the cell lysate was confirmed by Western blot analysis. As a result, as shown in FIG. 2, it was confirmed that the expression level of phospho-eNOS was increased in a concentration-dependent manner by treatment with CDCQ in vascular endothelial cells.
Example 4. In vascular endothelial cells, 3-caffeoyl-4- Dihydro caffe oil Quinic acid Treatment with NO ( nitric acid )
The degree of NO production in vascular endothelial cells was measured using DAF-FM diacetate (4-Amino-5-methylamino-2 ', 7'-difluorofluorescein diacetate, Molecular Probe, OR). The vascular endothelial cells were attached to 96-well plates at a density of 5 x 10 < 4 > cfu / ml. Cells were cultured in growth medium for 12 hours, cultured in medium lacking FBS (fetal bovine serum) at 37 ° C for 3 hours, treated with L-NAME (LN G- nitroarginine methyl ester, 100M) And then pretreated for 30 min. Then, the CDCQ of the present invention was treated for 60 minutes, the vascular endothelial cells were washed twice with PBS, and then treated with 10 μM of DAF-FM diacetate for 20 minutes. After the medium was removed, the cells were fixed with 4% paraformaldehyde as a fixing solution for 5 minutes, and the fluorescence was measured by replacing the medium with FBS-free medium. The excitation wavelength is 488 nm and when NO is bound to DAF, it fluoresces at 515 nm. FIG. 3 shows the results of measurements with a total internal fluorescence microscope (Nikon, Japan) and a microplate reader, showing that the production of NO by CDCQ treatment in vascular endothelial cells was concentration-dependent , Respectively.
Example 5. In vascular endothelial cells, 3-caffeoyl-4- Dihydro caffe oil Quinic acid Depending on the treatment phospho - eNOS And NO Confirmation of the expression pattern of the signal transduction-related protein
EA.hy926 cells were treated with 20 .mu.M CDCQ for 10, 30 and 60 minutes to obtain total cell lysates. Western blot analysis was performed to investigate the phospho - eNOS expression-related signaling proteins in the cell lysate As a result, as shown in FIG. 4, it was confirmed that CDCQ of the present invention increases the expression amount of PKA (protein kinase A) and CaMKIIa (calcium / calmodulin-dependent protein kinase). In order to confirm the relationship between the expression of the signal transduction proteins PKA and CaMKIIa and phospho - eNOS, inhibitors of PKA and CaMKIIa, H - 89 and KN - 93, respectively, were used. The vascular endothelial cells were pretreated with each inhibitor for 1 hour and then treated with 20 μM of CDCQ for 1 hour to obtain total cell lysate. Western blot analysis was performed to examine the expression level of phospho - eNOS in the cell lysate. Results As shown in FIG. 5, it was confirmed that the expression of PKA and CaMKIIa, which are signal transduction proteins in vascular endothelial cells, is involved in the expression of phospho - eNOS by CDCQ.
In order to confirm the relationship between expression of the signal transduction proteins PKA and CaMKIIa and NO production, H-89 and KN-93 inhibitors of PKA and CaMKIIa were added to vascular endothelial cells for 1 hour After pretreatment, 20 μM of CDCQ was treated for 1 hour and the degree of fluorescence was measured using DAF-FM diacetate (Molecular Probe, OR). FIG. 6 shows the results obtained by photographing with a total internal fluorescence microscope (Nikon, Japan) and a microplate analyzer, showing that PKA and CaMKIIa, which are signal transduction proteins, are involved in NO production by CDCQ in vascular endothelial cells .
Claims (7)
[Chemical Formula 1]
[Chemical Formula 1]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150171156A KR101834550B1 (en) | 2015-12-03 | 2015-12-03 | Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150171156A KR101834550B1 (en) | 2015-12-03 | 2015-12-03 | Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170065117A KR20170065117A (en) | 2017-06-13 |
KR101834550B1 true KR101834550B1 (en) | 2018-03-05 |
Family
ID=59218785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150171156A KR101834550B1 (en) | 2015-12-03 | 2015-12-03 | Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101834550B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220037530A (en) | 2020-09-17 | 2022-03-25 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of vascular disease |
-
2015
- 2015-12-03 KR KR1020150171156A patent/KR101834550B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
Man Hee Rhee 외 2명, Salicornia herbacea: Botanical, chemical and pharmacological review of halophyte marsh plant, Journal of Medicinal Plants Research Vol. 3(8), pp. 548-555, August, 2009년 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220037530A (en) | 2020-09-17 | 2022-03-25 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of vascular disease |
Also Published As
Publication number | Publication date |
---|---|
KR20170065117A (en) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110038959A1 (en) | Plant-origin drug for preventing or improving hyperuricemia | |
KR101449804B1 (en) | Antihypertensive composition comprising gelatin extract from skate skin and peptide isolated from the extract | |
EP2821068B1 (en) | Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin | |
KR101737854B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Sanguisorba officinalis L. | |
KR101590842B1 (en) | Aster glehni extracts, fractions or compounds isolated therefrom for the treatment or prevention of Hyperuricemia or Gout | |
KR101834550B1 (en) | Composition for preventing, improving or treating vascular diseases comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid as effective component | |
JP6628204B2 (en) | Xanthine oxidase inhibitor and method for producing the same | |
RU2713906C2 (en) | Novel compound (ks513) recovered from pseudolysimachion rotundum var. subintegrum, composition containing said compound as active ingredient, for preventing or treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and use thereof | |
KR102092729B1 (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
KR20150014267A (en) | Compositions for inhibiting the activity of neuraminidase containing geranylated flavonoids from Paulownia tomentosa as an effective ingredient | |
KR100490799B1 (en) | Food comprising an extract of bambusoideae plant or tricin isolated therefrom | |
KR101332074B1 (en) | Composition Comprising Esculetin for Inhibition of Bone Loss | |
KR101753560B1 (en) | Composition containing naringenin and hesperetin for preventing, treating or improving pancreatic cancer | |
KR101665875B1 (en) | Composition for treating prostate disease comprising korean native plants | |
KR20130082250A (en) | Composition for preventing or improving the hypertension containing parthenocissus tricuspidata extract | |
KR101470613B1 (en) | Composition comprising latifolin for preventing or treating inflammatory diseases | |
KR102198106B1 (en) | Composition for Preventing or Treating Vascular Disease Comprising Codonopsis lanceolata Extract Containing Lancemaside A | |
KR100696963B1 (en) | Composition containing an wogonin derivatives for protecting brain cells and treating brain stroke | |
KR20130082249A (en) | Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract | |
KR20240042861A (en) | Coumaroyl triterpene derivatives derived from Actinidia polygama and their use for preventing or treating diabetes | |
KR100550495B1 (en) | A pharmaceutical composition comprising the derivatives of amentoflavone isolated from Selaginella tamariscina for treating or preventing cardiovascular system disease | |
JP2011132173A (en) | Xanthine oxidase inhibitor and uric acid production inhibitor | |
KR20150111793A (en) | Anti-inflammatory agent containing pulchellamin g | |
KR100550494B1 (en) | Composition comprising the amentoflavone derivatives isolated from Selaginella tamariscina | |
KR101841537B1 (en) | A novel compound from Lithospermi radix derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |